A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.
Hirva Mamdani(Wayne State University), Shadia I. Jalal(Indiana University Health), Muhammad Furqan(University of Iowa), Kristen Pizana(The Barbara Ann Karmanos Cancer Institute), Seongho Kim(Wayne State University), Misty Dawn Shields(Indiana University Health), Qura Abid(The Barbara Ann Karmanos Cancer Institute), Ryan D. Gentzler(University of Virginia Health System)
Cited by 1
Related Papers
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
|Nature Medicine|2024|234
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125